Skip to main content

Table 2 Main anthropometric, clinical, functional, and radiological variables in patients with COPD, stratified according to disease severity (GOLD) and gender (mean ± SD, or proportion).

From: Characterisation of COPD heterogeneity in the ECLIPSE cohort

  GOLD II GOLD III GOLD IV Comparing
  Females
(n = 380)
Males
(n = 574)
p value Females
(n = 293)
Males
(n = 618)
p value Females
(n = 77)
Males
(n = 219)
p value GOLD stage within females GOLD stage within males
Clinical Data
Age (years) 63.0 ± 7.1 63.8 ± 7.3 0.043 62.6 ± 6.8 64.2 ± 7.0 < 0.001 60.7 ± 6.8 63.0 ± 7.0 0.012 0.034 0.075
Pack-years 41.1 ± 21.6 52.7 ± 31.4 < 0.001 42.6 ± 21.2 52.2 ± 27.0 < 0.001 41.1 ± 21.8 52.1 ± 28.4 < 0.001 0.547 0.640
Current smokers (%) 40 36 0.300 37 38 0.695 27 28 0.922 0.114 0.027
BMI (kg/m2) 27.2 ± 6.4 27.5 ± 5.2 0.066 25.6 ± 6.0 26.4 ± 5.2 0.008 23.4 ± 6.4 25.5 ± 5.3 0.001 < 0.001 < 0.001
FFMI (kg/m2) 16.2 ± 3.0 18.4 ± 2.6 < 0.001 15.4 ± 2.3 17.8 ± 2.6 < 0.001 14.8 ± 2.5 17.0 ± 2.4 < 0.001 < 0.001 < 0.001
mMRC score 1.4 ± 1.0 1.3 ± 1.0 0.645 1.9 ± 1.0 1.8 ± 1.0 0.050 2.3 ± 1.0 2.3 ± 1.0 0.975 < 0.001 < 0.001
SGRQ-C (total) 43.8 ± 20.2 41.6 ± 20.9 0.193 55.4 ± 18.0 53.4 ± 18.5 0.215 61.3 ± 15.6 61.8 ± 16.1 0.885 < 0.001 < 0.001
Number of exacerbationsa 0.8 ± 1.2 0.5 ± 0.9 < 0.001 1.2 ± 1.4 0.9 ± 1.3 0.005 1.5 ± 1.6 1.1 ± 1.4 0.044 < 0.001 < 0.001
Heart trouble (%) 19 30 < 0.001 17 30 < 0.001 22 27 0.343 0.632 0.687
Heart attack (%) 5 13 < 0.001 6 10 0.033 1 10 0.011 0.280 0.275
Stroke (%) 5 4 0.544 3 3 0.805 4 3 0.645 0.557 0.467
Heart failure (%) 4 9 0.002 3 8 0.003 11 9 0.597 0.007 0.884
Arrhythmia (%) 10 14 0.068 8 15 0.010 12 10 0.684 0.604 0.315
Osteoporosis (%) 28 5 < 0.001 32 7 < 0.001 29 7 < 0.001 0.601 0.415
Diabetes (%) 9 13 0.079 5 10 0.010 7 13 0.154 0.138 0.341
Inflammatory bowel disease (%) 9 4 0.003 6 3 0.016 12 4 0.019 0.156 0.308
Peptic ulcer (%) 10 12 0.283 10 11 0.728 11 7 0.239 0.959 0.082
Reflux/heartburn (%) 36 29 0.022 30 20 0.002 27 19 0.138 0.163 0.001
Depression requiring Tx (%) 23 11 < 0.001 32 10 < 0.001 26 12 0.004 0.036 0.846
Physiology
FEV1 (% predicted) 63.6 ± 8.2 62.8 ± 8.5 0.119 41.0 ± 5.8 40.0 ± 5.8 0.017 25.4 ± 3.2 24.5 ± 3.8 0.156 < 0.001 < 0.001
FEV1/FVC (%) 53.2 ± 8.8 52.5 ± 8.8 0.251 41.4 ± 8.9 40.0 ± 8.9 0.021 34.5 ± 8.0 31.2 ± 7.2 0.002 < 0.001 < 0.001
FEV1 reversibility (%) 10.6 ± 12.1 11.7 ± 13.0 0.056 10.3 ± 14.8 11.4 ± 14.5 0.316 5.5 ± 13.2 8.9 ± 14.0 0.037 0.002 0.007
6MWD (metres) 391 ± 113 415 ± 110 0.003 333 ± 119 366 ± 116 < 0.001 265 ± 118 297 ± 119 0.069 < 0.001 < 0.001
BODE Index 1.7 ± 1.4 1.6 ± 1.3 0.715 4.2 ± 1.6 3.8 ± 1.6 < 0.001 6.0 ± 1.6 5.6 ± 1.6 0.079 < 0.001 < 0.001
Imaging
Emphysema (%) 11.2 ± 9.5 12.7 ± 9.5 0.002 20.1 ± 11.7 20.0 ± 11.5 0.876 27.1 ± 13.7 28.6 ± 12.1 0.435 < 0.001 < 0.001
Bronchiectasis (%) < 1 2 0.057 3 6 0.044 9 7 0.468 < 0.001 0.003
  1. a In the year prior to study entry.
  2. Abbreviations: tx: treatment.